Wellness Company Wholeleaf Secures ₹1.5 Crore in Seed Funding Round

An all-natural pain therapeutics company, Wholeleaf, has raised ₹1.5 Cr in a seed funding round backed by investors like Aman Gupta – Cofounder and CMO of BOAT, Namita Thapar – Executive Director of Emcure Pharmaceuticals, and Kanika Tekriwal – CEO of JetSetGo, on the recent Shark Tank India Season 5.

The company had earlier raised ₹4 Cr in a funding round that saw participation from institutional investors and notable angel investors.

According to the company, the newly-raised funds will be used for online expansion via D2C as well as offline retail presence across key cities, strengthening doctor engagement, and accelerating product awareness. The wellness brand also plans to deploy funds towards clinical collaborations and research-led product development to further create medically informed formulations.

Founded in 2020 by Shivraj Sharma, the Gurgaon-based startup’s proprietary Ayurveda formulations combine cannabinoids with clinically relevant super herbs to deliver effective, long-term pain management solutions. Its product portfolio includes topical applications, roll-ons, oils, and sprays designed to address chronic pain conditions affecting joints, muscles, and nerves.

Since inception, the company claims to have served over 1,00,000 customers across the country and built a strong repeat-consumer base bolstered by an expanding network of medical practitioners. Currently operational through e-commerce and quick commerce platforms, as well as leading pharmacy chains and digital platforms such as the Apollo Pharmacy network, the brand is now preparing to expand its presence across major metropolitan markets including Mumbai, Bengaluru, Hyderabad, Kolkata and Chennai.

Speaking on the announcement, Shivraj Sharma, Founder and CEO of Wholeleaf, said, “Chronic pain has remained under-addressed for millions of Indians who seek safer, natural, and long-term solutions. At Wholeleaf, we are building clinically informed, plant-based pain therapeutics that both consumers and medical professionals can trust. This fundraise allows us to expand our reach, collaborate more closely with the medical community, and invest in research-led product development. Our vision is to make natural pain relief mainstream, credible, and globally competitive.”

Over the next 12 to 18 months, the company plans to focus on scaling operations responsibly, maintaining strong unit economics, and progressing toward sustained profitability.